The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and 108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination of pseudouridine and creatinine was applied.
Introduction
Malignant growth is accompanied by a rapid turnover of nucleic acids. Nucleic acid turnover may be evaluated by measuring its synthesis as well as degradation rate. RNA molecules contain both nucleosides and modified nucleosides formed post-transcriptionally by the action of modifying enzymes. In contrast to nucleosides, most of the modified RNA catabolites are not reutilized in nucleotide synthesis by salvage pathways, nor are they further degraded. Modified nucleosides released from RNA molecules in the cell appear in extracellular fluid, as well as blood plasma, and they are excreted in urine, some of them quantitatively (1, 2) . The measurement of urinary excretion of pseudouridine, 7-methylguanine, and N 2 ,N 2 -dimethyl-guanosine was used to assess whole-body turnover of rRNA, mRNA, and tRNA in preterm infants and adults (3, 4) . Pseudouridine is generally excreted in concentrations of 10 to 100 times that of other nucleosides, both in healthy subjects and cancer patients (5, 6) . The source of pseudouridine detected in urine is whole-body catabolism of tRNA and rRNA (3, 4) . Among several modified nucleosides tested, pseudouridine is the compound of choice for investigation in the follow up of neoplastic disease (5) . There is a considerable number of publications concerning changes in urinary pseudouridine excretion as a response to malignant growth (6 -14) . There is much less information about changes in blood plasma concentrations of pseudouridine, which is 100 times lower than in urine, although it can still be determined precisely with HPLC techniques (15) (16) (17) (18) cleosides are its approximately 100-fold greater concentration in blood plasma, and its lesser variability attributable to the renal clearance rate, sex-related differences, genetic influences or environmental conditions (19) . There are only a'few reports indicating the elevation of serum pseudouridine concentrations in patients suffering from neoplastic diseases (5, 17, 20, 21 ).
The present experiment was undertaken to extend the above studies and to estimate blood plasma pseudouridine concentrations in adult healthy subjects of variable age and sex, and patients suffering from malignant proliferative diseases. Sample preparation and analytical procedure Peripheral blood (2 ml) was drawn into a heparinized syringe prior to the morning meal. Immediately after sampling, whole blood was centrifuged at 2500 g for 10 min at 4 °C. Two volumes of ice-cold fresh trichloroacetic acid solution (80 g/1) were added to the blood plasma, and the resulting precipitate removed by centrifugation. The supernatant was then extracted three times with 1.5 volumes of water-saturated diethyl ether to remove the trichioroacetic acid. The aqueous layer was passed through a 0.45 μηι Millipore filter prior to analysis.
Materials and Methods

Patients
In order to calculate the rate of urinary pseudouridine excretion and the renal clearance of this nucleoside under physiological conditions, twenty-four hour collection of urine was performed in 30 healthy individuals. Urine samples were purified using Cig SEP-PAK Waters Associates cartridges.
Pseudouridine and creatinine concentrations were determined according to the method described by Simmonds & Harkness (16) . High performance liquid chromatography (HPLC) was performed with an isocratic liquid Chromatograph "Beckman 330" using an ultrasphere Altex column ODS 5 μηι, 4.6 · 250 mm, RP-18 cartridge precolumn (4.6 · 30 mm) and RP-18 guard cartridge (3.2 · 15 mm) -Pierce. The absorbance was measured by a UV detector "Beckman 153" equipped with a 254 nm filter. For registration and integration of results, an integratorrecorder "Shimadzu R-R3A" was used. The mobile phase was 0.01 mol -I"" 1 potassium dihydrogen phosphate (pH 5.9) containing 10 ml/1 methanol, at a flow rate of 1 ml · min"
1 . An example of the blood plasma chromatogram of purine and pyrirnidine compounds is presented in figure 1 .
Statistical analysis
All data were stored in a database using a dBase3p programme, then transferred to a STATGRAPH program for graphic and statistical evaluation.
Results
The relationship between age and plasma pseudouridine concentration in 104 healthy adults is presented in figure 2 . There was a statistically significant positive correlation between age (in the range of 20 and 92 years of age) and pseudouridine concentration in blood plasma (μπιοί -I" 1 )· The average pseudouridine concentration in both males and females was 2.35 and 2.61 μιηοΐ · I"" 1 (differences non-significant), at the average ages of 30 and 58, respectively. The correla- 30 14.32 ± 5.20 30 19.60 ± 5.22 30 4.04 ± 0.99 the plasma of patients with chronic lymphocytic leukaemia was independent of the stage of the disease, i. e. it was elevated to the same extent both in early stages (0, I) and advanced stages (II, III, arid IV) of leukaemia (clinical classification according to Rai et al. (22) The relationship between the expansion of examined lung, gastric, and large intestine cancers and plasma pseudouridine concentrations is presented in figure 4 . In the case of large intestine cancer (adenocarcinoma of the colon and adenocarcinoma of the rectum) only three patients (two with primary focus and one with dissemination) had plasma pseudouridine concentrations within control values (mean ± SD). In patients with lung cancer an evident increase of plasma pseudouridine concentrations was seen only during dissemination. A relatively low response, independent of disease progression, was observed in patients with gastric adenocarcinoma (fig. 4) . •Ί r "".:.
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Discussion
The mean physiological concentration of pseudouridine in blood plasma (tab. 2) is similar to that observed in serum by Russo et al. (17) (27) indicates that practically all the data collected with the various procedures agree within quite narrow limits. Rising plasma pseudouridine concentrations in healthy adults in our studies ( fig. 2 ) may reflect an age-related increase in the catabolism of whole-body rRNA + tRNA and/or renal insufficiency. The advantage of the applied HPLC method is a simultaneous determination of pseudouridine and creatinine ( fig. 1) , and thus the possibility of a direct calculation of plasma pseudouridine in relation to the creatinine concentrations. Such an expression of the pseudouridine concentration takes into account changes in dilution of blood plasma resulting from an increased or decreased supply of water (e. g. absorption from the gastrointestinal tract, parenteral infusions) and impaired kidney function. Our recent study (28) showed that pseudouridine accumulates markedly in blood plasma (25 times higher concentration than physiological) in patients with chronic renal failure. Among examined purines and pyrimidines, pseudouridine had the lowest efficiency of haermodialysis (44%) and the longest t 1/2 (relative to-creatinine) in plasma. In the present study, calculation of plasma pseudouridine in relation to creatinine concentration largely abolished the variability of pseudouridine with age. According to Salvatore et al. (27) the serum "pseudouridine index" (pseudouridine: creatinine ratio) almost equalled the reference pseudburidine values for normal subjects. In healthy subjects renal pseudouridine clearance is lower than clearance of endogenous creatinine (tab. 2), which indicates that pseudouridine can be partially reabsorbed in renal tubules. The ratio of pseudouridine vs. creatinine in blood plasma to that in urine (1.48) was comparable to that reported by Topp et al. (25) . The method described by Kuo et al. (15) allowed the separation and quantification of other modified nucleosides in serum using reversedphase HPLC with diode-array measurement. The concentrations of other nucleosides in blood serum are also consistently elevated in patients with malignant proliferative diseases (15, 29) , but it should be noted that their blood plasma concentrations are 100 times less than that of pseudouridine, and their concentrations also display greater variability, due to nonmetabolic factors (19) .
The relative independence of plasma pseudouridine concentrations on non-metabolic factors, when calculated per unit of creatinine, encouraged us to use this form of pseudouridine expression in neoplastic cases. In general, results of pseudouridine concentration in blood plasma expressed in absolute values (μηιοί · I"" 1 ) correlate (r = 0.51) with relative values (mmol -mol"" 1 creatinine), but not in all examined patients. Among haematological neoplasms the highest concentration of pseudouridine was observed in the plasma of patients suffering from multiple myeloma and chronic lymphocytic leukaemia ( fig. 3 ). This is in agreement with the findings of Sorensen et al. (6) , who demonstrated that urinary pseudouridine excretion in multiple myeloma usually exceeds that in other neoplasms, and there is a highly significant linear trend towards a negative prognosis with a rising concentration of urinary pseudouridine. It is interesting that in mice carrying a transplantable myeloma tumour no increase in the serum pseudouridine concentration was seen, despite the presence of a considerable tumour burden (30) . Our resultsMndicate that the plasma pseudouridine concentration in patients with multiple myeloma depends on tumour mass, since the lowest concentration of this modified nucleoside was observed in remission and stage I A , and the highest in stage III B of the disease ( fig. 3 ).
There are several reports indicating increased urinary pseudouridine excretion in children and adults with different types of leukaemia (8 -11, 31, 32) . We could found no corresponding literature data for blood plasma pseudouridine concentrations in chronic lymphocytic leukaemia. A single literature source (27) reports that serum pseudouridine concentrations in three patients with chronic lymphocytic leukaemia ranged from 10.64 to 31.37 μιηοΐ · I" 1 . In contrast to multiple myeloma, the plasma pseudouridine concentration in chronic lymphocytic leukaemia does not seem to be dependent on disease progression ( fig. 3) . A considerable increase of the pseudouridine concentration was observed both in early and advanced stages of leukaemia. We suppose that the plasma pseudouridine concentration might reflect proliferative activity of lymphoidal cells. However, a greater number of cases should be examined, in order to distinguish between various types of chronic lymphocytic leukaemia, characterized by more or less active proliferation. It is interesting that chronic lymphocytic leukaemia leads to a generally higher concentration of pseudouridine in blood plasma than nor\-Hodgkin's lymphoma, in spite of the clinically less dynamic progression of the disease. Our recent studies demonstrated a significant increase in urinary pseudouridine excretion in patients with multiple myeloma, chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, without significant changes in Hodgkin's disease and polycythaemia vera (33) .
Rapid turnover of rRNA + tRNA is characteristic of certain cancers of the gastrointestinal tract, especially large intestine adenocarcinomas.
However, in these cases the plasma pseudouridine concentration was independent in disease progression, since elevated concentrations of pseudouridine in plasma were observed both in patients with early and advances stages (fig. 4) . A relatively low response was observed in patients suffering from gastric and pancreatic adenocarcinoma. It is interesting that gastric adenocarcinoma, in contrast to other cancers of the gastrointestinal tract (e. g. large intestine adenocarcinomas), did not affect urinary pseudouridine excretion independently of the stage of the disease (33) . In patients with lung cancer, the plasma pseudouridine concentration seems to be dependent on dissemination of the disease, and it increased in advanced cases with metastases ( fig. 4) . The elevation of plasma pseudouridine concentration leads to increased urinary pseudouridine excretion in patients with lung cancer (33) . McEntire et al. (21) showed that precise measurement of an array of 29 nucleosides in serum with subsequent data modelling may provide a clinically useful approach to patient classification in diagnosis of lung cancer and subsequent therapeutic monitoring. The elevated plasma pseudouridine concentration was also evident in all examined cases of cancer of the urogenital system: cancer of the urinary bladder, cancer of the kidney, cancer of the prostate, and cancer of the testis. Recently, Rasmuson et al. (34) demonstrated that increased urinary pseudouridine excretion can be an independent prognostic factor in renal cell carcinoma. The concentration of pseudouridine correlated to tumour grade and tumour size. Survival time was also significantly reduced in patients with increased pseudouridine excretion.
In conclusion, we can say that the determination of pseudouridine in blood plasma, particularly in relation to creatinine, is a valuable biochemical marker of accelerated turnover rate of nucleic acids associated with neoplastic growth. The most evident response in blood plasma pseudouridine concentrations, noticed in early stages of malignant growth, is characteristic of patients with chronic lymphocytie leukaemia and large intestine cancers. '
